Any current/future new fundraising through debt or equity?

As of the latest update in February 2025, Concord Biotech has indicated that CapEx is largely complete, particularly for the injectable unit with INR 225 crores spent, which will be capitalized. For FY '25, there is no expectation of growth CapEx; only maintenance CapEx around INR 15-20 crores per annum is planned. The company mentioned that if new opportunities arise in fermentation or adjacent areas, they may consider in-house or external investments, but no specific plans for new fundraising through debt or equity were disclosed. Overall, there is no explicit mention of any current or immin

Any current/future capex/capital investment/strategic investment?

Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized. No significant growth capex expected for FY '24-'25; only maintenance capex of around INR 15-20 crores per annum anticipated. Future capex may be considered if new opportunities arise within or adjacent to fermentation APIs, either in-house or through procurement. Strategic investment: Concord will acquire a 26% equity stake in CleanMax Private Limited and CleanMax Enviro Energy Solutions (renewable energy provider in Gujarat). This investment supports sustainability goals by p

Future growth expectations in sales/revenue/volumes?

Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years. Growth is expected from both API and formulation segments, with API contributing around 80% and formulations about 20%. API third-party sales are anticipated to grow at around 10-12%, while formulations, especially due to capacity ramp-up, are expected to grow north of 40% to achieve overall 20%+ company growth. Injectables are expected to gradually contribute more, with asset turnovers of INR 300-600 crores and a phased ramp-up over 5 years contributing about 6% growth. Growth is volume-drive

Current/ Expected Orderbook/ Pending Orders?

Concord Biotech has a strong order book position as of Q3 FY '25. Certain opportunities are currently active and anticipated to convert within the quarter. Some customer orders faced delays, pushing certain order executions from Q3 to Q4. There is a possibility, though less likely, that some orders may move beyond Q4 into Q1. The company remains confident in execution based on January and February performance. Management is actively working on new customer acquisitions and expanding market share. No specific numeric order book value disclosed, but execution visibility is positive with ongoing

IN US

Sale is live|00:00:00left today

Concord Biotech LtdQ4 FY26Pharmaceuticals & Biotechnology

Concord Biotech Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,295P/E: 37.4Market Cap: ₹11.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years.
→Growth is expected from both API and formulation segments, with API contributing around 80% and formulations about 20%.
→API third-party sales are anticipated to grow at around 10-12%, while formulations, especially due to capacity ramp-up, are expected to grow north of 40% to achieve overall 20%+ company growth.
→Injectables are expected to gradually contribute more, with asset turnovers of INR 300-600 crores and a phased ramp-up over 5 years contributing about 6% growth.
→Growth is volume-driven with stable pricing; no significant price hikes anticipated.
→Capacity utilization at key units (Unit 1: 78%, Unit 3: 35%) is expected to increase, supporting growth.
→Growth opportunities exist in fermentation APIs and CDMO space, including peptides, but these are in early stages.

Margin guidance

Category 3

- Concord Biotech targets a 20% to 25% CAGR growth in sales over the next 3 to 5 years at the company level. - API sales (third-party) are expected to grow at about 10% to 12%, reflecting its mature status. - Formulation sales are anticipated to grow over 40%, driven by capacity ramp-ups and new injectable product contributions. - EBITDA margins are projected to remain stable in the 40%-43% range, with potential upside as injectable facilities ramp up. - Profit after tax growth tracked 9% Y-o-Y for the 9 months ended Dec 2024; with the expected sales growth, PAT should improve accordingly. - Growth will be volume-driven, with stable pricing and limited significant price hikes. - The journey to 25% CAGR may be stepwise, with stronger growth expected in FY '26 and beyond as injectables and formulations contribute more. - CapEx for FY '25 and FY '26 will be minimal, focusing on maintaining current capacities. Overall, Concord expects improving earnings driven by formulation ramp-up and steady API growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→As of the latest update in February 2025, Concord Biotech has indicated that CapEx is largely complete, particularly for the injectable unit with INR 225 crores spent, which will be capitalized.
→For FY '25, there is no expectation of growth CapEx; only maintenance CapEx around INR 15-20 crores per annum is planned.
→The company mentioned that if new opportunities arise in fermentation or adjacent areas, they may consider in-house or external investments, but no specific plans for new fundraising through debt or equity were disclosed.
→Overall, there is no explicit mention of any current or imminent fundraising via debt or equity in the provided material.

Order book

Yes

→Concord Biotech has a strong order book position as of Q3 FY '25.
→Certain opportunities are currently active and anticipated to convert within the quarter.
→Some customer orders faced delays, pushing certain order executions from Q3 to Q4.
→There is a possibility, though less likely, that some orders may move beyond Q4 into Q1.
→The company remains confident in execution based on January and February performance.
→Management is actively working on new customer acquisitions and expanding market share.
→No specific numeric order book value disclosed, but execution visibility is positive with ongoing momentum.

Capex plans

→Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized.
→No significant growth capex expected for FY '24-'25; only maintenance capex of around INR 15-20 crores per annum anticipated.
→Future capex may be considered if new opportunities arise within or adjacent to fermentation APIs, either in-house or through procurement.
→Strategic investment: Concord will acquire a 26% equity stake in CleanMax Private Limited and CleanMax Enviro Energy Solutions (renewable energy provider in Gujarat).
→This investment supports sustainability goals by powering the Dholka plant with 6.6 MW wind and 3.3 MW DC solar capacity, reducing carbon footprint and energy costs.
→Injectable plant is scheduled to begin commercial production this quarter, with expected ramp-up and contribution to revenue and profitability in the coming years.

How does Concord Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Concord Biotech Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Concord Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio